Clinical Trial

Primary Radiotherapy In MEtastatic Lung Cancer

Study acronym: PRIME-Lung
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Lung cancer has the highest mortality rate of all cancers in Australia and is an area of unmet need. It starts in the lung (the primary tumour), and then spreads (metastasise) to other organs. The PRIME-Lung clinical trial will investigate if radiotherapy to the primary lung tumour, in addition to standard drug therapies, for patients with metastatic lung cancer will lead to less spread of cancer, prolong life, improve patient well-being and be cost-effective for the health care system.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2029-01-01 -> 2030-12-31 2026-08-01
minor Completion pushed: 2033-01-01 -> 2036-12-31 2026-08-01
Trial Details
NCT Number NCT07135882
Lead Sponsor Trans Tasman Radiation Oncology Group
Collaborators: Thoracic Oncology Group of Australasia (TOGA)
Conditions Carcinoma, Non-Small-Cell Lung (NSCLC)
Enrollment 420 participants
Start Date 2026-08-25
Primary Completion 2030-12-31 (estimated)
Study Completion 2036-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-31